October 18, 2006 -- Trubion priced its IPO at $13 per share, the low end of the range, but the more important fact is that the range held. Trubion is not a company that in-licenses drugs from other companies. Nor does it have a drug in Phase III trials. So the list of accomplishments is a little slim, but the IPO results are strong. What gives? We look at the research program at Trubion and its big pharma partnership...
